{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:01:19Z","timestamp":1776492079489,"version":"3.51.2"},"reference-count":43,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A640323"],"award-info":[{"award-number":["N42A640323"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2023,10,2]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Currently, there is no head-to-head comparison of novel pharmacological treatments for heart failure with reduced ejection fraction (HFrEF). A network meta-analysis aimed to compare effects of both conventional and alternative drug combinations on time to develop primary composite outcome of cardiovascular death or heart failure hospitalisation (PCO).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Randomised controlled trials (RCTs) were identified from Medline, Scopus up to June 2021. The RCTs were included if comparing any single or combination of drugs, that is, ACE inhibitors (ACEI), angiotensin receptor blockers, beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), ivabradine (IVA), angiotensin receptor blocker\/neprilysin inhibitors (ARNI) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), soluble guanylyl cyclase and omecamtiv mecarbil and reporting PCO. Data were extracted from Kaplan-Meier curves, individual patient data were generated. A mixed-effect Weibull regression was applied. Median time to PCO, HRs with 95% CI were estimated accordingly. Our findings suggested that ACEI+BB+MRA+SGLT2i, BB+MRA+ARNI, and ACEI+BB+MRA+IVA had lower probability of PCOs than the conventional triple therapy (ACEI+BB+MRA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median time to PCOs of ACEI+BB+MRA was 57.7 months whereas median times to those new combinations were longer than 57.7 months. In addition, the three new regimens had a significantly lower PCO risks than ACEI+BB+MRA, with the HRs (95% CI) of 0.51 (0.43 to 0.61), 0.55 (0.46 to 0.65) and 0.56 (0.47 to 0.67), accordingly.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study suggested that SGLT2i, ARNI and IVA in addition to ACEI+BB+MRA may be better in prolonging time to develop PCO in HFrEF patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2023-002364","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T11:52:01Z","timestamp":1699444321000},"page":"e002364","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5496-6861","authenticated-orcid":false,"given":"Thanakit","family":"Suebsaicharoen","sequence":"first","affiliation":[{"name":"Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puri","family":"Chunekamrai","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teerapat","family":"Yingchoncharoen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarit","family":"Tansawet","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand"},{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanaphruet","family":"Issarawattana","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawin","family":"Numthavaj","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"2025081710553924000_10.2.e002364.1","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2025081710553924000_10.2.e002364.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"2025081710553924000_10.2.e002364.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"2025081710553924000_10.2.e002364.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605233342101"},{"key":"2025081710553924000_10.2.e002364.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"2025081710553924000_10.2.e002364.6","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"The Lancet"},{"key":"2025081710553924000_10.2.e002364.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"2025081710553924000_10.2.e002364.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"2025081710553924000_10.2.e002364.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"2025081710553924000_10.2.e002364.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"2025081710553924000_10.2.e002364.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"2025081710553924000_10.2.e002364.12","first-page":"1497","article-title":"Vericiguat in heart failure with reduced ejection fraction. reply","volume":"383","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2025081710553924000_10.2.e002364.13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with Omecamtiv Mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"2025081710553924000_10.2.e002364.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2025081710553924000_10.2.e002364.15","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001063"},{"key":"2025081710553924000_10.2.e002364.16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10557-020-07099-2","article-title":"Relative efficacy of Sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis","volume":"35","author":"Aimo","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025081710553924000_10.2.e002364.17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ehjcvp\/pvab088","article-title":"Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction and chronic kidney disease already receiving Neurohormonal inhibitors: a network meta-analysis","volume":"8","author":"Ameri","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025081710553924000_10.2.e002364.18","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.787810","article-title":"Comparative efficacy of medical treatments for chronic heart failure: a network meta-analysis","volume":"8","author":"Xiang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2025081710553924000_10.2.e002364.19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/joim.13487","article-title":"Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction","volume":"292","author":"De Marzo","year":"2022","journal-title":"J Intern Med"},{"key":"2025081710553924000_10.2.e002364.20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11020348","article-title":"Prognostic benefit of new drugs for HFrEF: a systematic review and network meta-analysis","volume":"11","author":"Pagnesi","year":"2022","journal-title":"J Clin Med"},{"key":"2025081710553924000_10.2.e002364.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2021.09.004"},{"key":"2025081710553924000_10.2.e002364.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.12.010"},{"key":"2025081710553924000_10.2.e002364.23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2025081710553924000_10.2.e002364.24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2025081710553924000_10.2.e002364.25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-021-01098-3","article-title":"Comparing Sacubitril\/valsartan against sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and network meta-analysis","volume":"42","author":"Teo","year":"2022","journal-title":"Clin Drug Investig"},{"key":"2025081710553924000_10.2.e002364.26","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan-Meier curves","volume":"17","author":"Wei","year":"2017","journal-title":"Stata J"},{"key":"2025081710553924000_10.2.e002364.27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/1536867X19893639","article-title":"Multilevel mixed-effects parametric survival analysis: estimation, simulation, and application","volume":"19","author":"Crowther","year":"2019","journal-title":"Stata J"},{"key":"2025081710553924000_10.2.e002364.28","doi-asserted-by":"crossref","DOI":"10.1002\/cl2.1080","article-title":"Cinema: software for Semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"2025081710553924000_10.2.e002364.29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J Hypertens"},{"key":"2025081710553924000_10.2.e002364.30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"2025081710553924000_10.2.e002364.31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1253\/circj.CJ-17-0323","article-title":"Randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF)","volume":"82","author":"Tsutsui","year":"2017","journal-title":"Circ J"},{"key":"2025081710553924000_10.2.e002364.32","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2025081710553924000_10.2.e002364.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4670-7"},{"key":"2025081710553924000_10.2.e002364.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14283-3"},{"key":"2025081710553924000_10.2.e002364.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492"},{"key":"2025081710553924000_10.2.e002364.36","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","article-title":"Efficacy and safety of Ivabradine in Japanese patients with chronic heart Failure\u2015 J-SHIFT study","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"2025081710553924000_10.2.e002364.37","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1253\/circj.CJ-18-0939","article-title":"A paradigm shift for heart failure treatment in Japan","volume":"82","author":"Min","year":"2018","journal-title":"Circ J"},{"key":"2025081710553924000_10.2.e002364.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105313442202"},{"key":"2025081710553924000_10.2.e002364.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02213-3"},{"key":"2025081710553924000_10.2.e002364.40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MAJ.0b013e31829dd6b1","article-title":"Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms","volume":"347","author":"Vizzardi","year":"2014","journal-title":"Am J Med Sci"},{"key":"2025081710553924000_10.2.e002364.41","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.4.1765"},{"key":"2025081710553924000_10.2.e002364.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01187-2"},{"key":"2025081710553924000_10.2.e002364.43","doi-asserted-by":"publisher","DOI":"10.1186\/CVM-2-1-020"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2023-002364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T17:55:52Z","timestamp":1755453352000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2023-002364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,11,8]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/openhrt-2023-002364"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2023-002364","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}